News | April 24, 2008

SCAI, ACC Return to Individual Scientific Sessions in 2009

April 25, 2008 - The Society for Cardiovascular Angiography and Interventions (SCAI) and the American College of Cardiology (ACC) will return to the traditional individual meeting formats for both the SCAI Annual Scientific Sessions and i2 Summit in 2009, in response to SCAI members' request for more a intimate meeting.

In 2008, SCAI and ACC partnered to hold the SCAI Annual Scientific Sessions in Partnership with ACCi2 Summit (SCAI-ACCi2), held in conjunction with ACC's Annual Scientific Session in Chicago.

"This year's SCAI-ACCi2 meeting was a strong achievement, particularly in terms of securing increased positive attention for our field,"? said SCAI President Bonnie H. Weiner, M.D. "Yet SCAI's members are enthusiastic about a return to the intimacy of a meeting with a targeted focus on high-level interventional cardiology. We look forward to continuing to look for ways to provide venues to educate both general and interventional cardiology communities so that we may learn from one another and, as always, provide the most optimal care to all cardiology patients."

"The ACC continues to be committed to serving the needs of our interventional members, and we look forward to a successful 2009 ACC i2 Summit that will build upon the success of this meeting over the past three years," said W. Douglas Weaver, president of the ACC. "Our relationship with SCAI remains strong, and we will continue to collaborate on various initiatives including education, guidelines and advocacy."

For more information: www.scai.org and www.acc.org

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init